/ENZY.ST
ENZY.ST Stock - Enzymatica AB (publ)
Healthcare|Drug Manufacturers - Specialty & GenericSTO
$1.91+1.87%
+$0.04 (+1.87%) • Dec 23
59
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.18
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $2.10
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ENZY.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.89 – $1.92
TARGET (TP)$2.19
STOP LOSS$1.75
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.26
52W High$5.45
52W Low$1.34
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $45.58M | $50.90M | $48.95M | $57.24M | $111.25M |
| Gross Profit | $30.72M | $31.86M | $28.45M | $33.35M | $75.96M |
| Gross Margin | 67.4% | 62.6% | 58.1% | 58.3% | 68.3% |
| Operating Income | $-52,055,000 | $-48,062,000 | $-68,217,000 | $-45,247,000 | $-12,062,000 |
| Net Income | $-53,179,000 | $-49,728,000 | $-68,657,000 | $-45,393,000 | $-13,221,000 |
| Net Margin | -116.7% | -97.7% | -140.3% | -79.3% | -11.9% |
| EPS | $-0.28 | $-0.28 | $-0.41 | $-0.31 | $-0.09 |
Company Overview
Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases. The company's product includes ColdZyme mouth spray, which prevents common cold and reduces the duration of illness. It also provides enzyme formulations. The company sells mouth spray under the ViruProtect brand in Denmark; STADAProtect brand in Germany; Psysiomer Stop Virus brand in France; and Zerinol Virus Defense brand in Italy. Enzymatica AB was incorporated in 2007 and is headquartered in Lund, Sweden.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ENZY.STBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.03
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 27, 2026 | — | — | — | — |
Q1 2026 | Feb 16, 2026 | — | — | — | — |
Q4 2025 | Oct 30, 2025 | — | $-0.03 | — | — |
Q3 2025 | Jul 17, 2025 | — | $-0.06 | — | — |
Q2 2025 | Apr 29, 2025 | — | $-0.07 | — | — |
Q1 2025 | Feb 18, 2025 | — | $-0.05 | — | — |
Q4 2024 | Nov 7, 2024 | — | $-0.04 | — | — |
Q3 2024 | Jul 18, 2024 | — | $-0.08 | — | — |
Q2 2024 | Apr 25, 2024 | — | $-0.11 | — | — |
Q1 2024 | Feb 16, 2024 | — | $-0.09 | — | — |
Q4 2023 | Nov 7, 2023 | — | $-0.06 | — | — |
Q3 2023 | Jul 18, 2023 | — | $-0.07 | — | — |
Q2 2023 | Apr 27, 2023 | — | $-0.09 | — | — |
Q1 2023 | Feb 17, 2023 | — | $-0.14 | — | — |
Q4 2022 | Nov 2, 2022 | — | $-0.08 | — | — |
Q3 2022 | Jul 19, 2022 | — | $-0.10 | — | — |
Q2 2022 | Apr 28, 2022 | — | $-0.12 | — | — |
Q1 2022 | Feb 17, 2022 | — | $-0.07 | — | — |
Q4 2021 | Nov 2, 2021 | — | $-0.04 | — | — |
Q3 2021 | Jul 16, 2021 | — | $-0.14 | — | — |
Latest News
Loading news...
Frequently Asked Questions about ENZY.ST
What is ENZY.ST's current stock price?
Enzymatica AB (publ) (ENZY.ST) is currently trading at $1.91 per share. The stock has moved +1.87% today.
What is the analyst price target for ENZY.ST?
No analyst price targets are currently available for this stock.
What sector is Enzymatica AB (publ) in?
Enzymatica AB (publ) operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the STO exchange.
What is ENZY.ST's market cap?
Enzymatica AB (publ) has a market capitalization of $0.46 billion, making it a small-cap company.
Does ENZY.ST pay dividends?
No, Enzymatica AB (publ) does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACE.ST
Ascelia Pharma AB (publ)
$3.17
Mkt Cap: $0.4B
ALZCUR.ST
AlzeCure Pharma AB (publ)
$2.08
Mkt Cap: $0.2B
CLBIO.ST
Corline Biomedical AB
$16.35
Mkt Cap: $0.4B
ERMA.ST
Enorama Pharma AB (publ)
$2.30
Mkt Cap: $0.2B
FLUO.ST
FluoGuide A/S
$36.20
Mkt Cap: $0.5B
IMMU.ST
Mendus AB (publ)
$5.30
Mkt Cap: $0.3B
MAGLE.ST
Magle Chemoswed Holding AB (publ)
$17.20
Mkt Cap: $0.4B
MOB.ST
Moberg Pharma AB (publ)
$10.04
Mkt Cap: $0.5B
NANEXA.ST
Nanexa AB (publ)
$4.21
Mkt Cap: $0.7B
XINT.ST
Xintela AB (publ)
$0.27
Mkt Cap: $0.2B
Explore stocks similar to ENZY.ST for comparison